A phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

American Journal of Hematology

Volumn 85, Issue 6, 2010, Pages 409-413

  Dispenzieri, Angela ^a   Wiseman, Gregory A ^a   Lacy, Martha Q ^a   Hayman, Suzanne R ^a   Kumar, Shaji K ^a   Buadi, Francis ^a   Dingli, David ^a   Laumann, Krista M ^a   Allred, Jake ^a   Geyer, Susan M ^b   Litzow, Mark R ^a   Gastineau, Dennis A ^a   Inwards, David J ^a   Micallef, Ivana N ^a   Ansell, Stephen M ^a   Porrata, Luis ^a   Elliott, Michelle A ^a   Johnston, Patrick B ^a   Hogan, William J ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; PENICILLIN G; PREDNISOLONE; QUINOLONE DERIVATIVE; VALGANCICLOVIR;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BONE MARROW; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSIMETRY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT REJECTION; HEADACHE; HEMATURIA; HUMAN; HYPOCALCEMIA; INFECTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PARENTERAL NUTRITION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SALVAGE THERAPY; SAMARIUM; TISSUE DISTRIBUTION; TRANSPLANTATION CONDITIONING;

EID: 77953055388     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21696     Document Type: Article

References (35)

1. Rajkumar SV, GertzMA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc 2002;77:813-822.
2. Kyle RA, GertzMA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
3. Mcelwain T, Powles R. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822-824. (Pubitemid 13013370)
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [see comments]. N Engl J Med 1996;335:91-97.
5. Child JA, Morgan GJ, Davies FE, Medical research council adult leukaemia working party, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
6. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
7. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441.
8. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(1) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858-1868.
9. Gahrton G, Svensson H, Cavo M, et al. The European group for B, marrow T. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-8 at European group for blood and marrow transplantation centres. Br J Haematol 2001;113:209-216.
10. Bjorkstrand B. European group for blood and marrow transplantation registry studies in multiple myeloma. Semin Hematol 2001;38:219-225. (Pubitemid 32717659)
11. Goeckeler WF, TroutnerDE, Volkert WA, et al. 153Sm radiotherapeutic bone agents. Int J Rad Appl Instrum B 1986;13:479-482.
12. Goeckeler WF, Stoneburner LK, Kasi LP, et al. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl Med Biol 1993;20:657-661.
13. Ketring AR. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B 1987;14:223-232.
14. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989;30:1814-1818. (Pubitemid 19279785)
15. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of samarium- 153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989;7:1926-1931.
16. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27:1084-1086.
17. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 1993;34:1839-1844. (Pubitemid 23331244)
18. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001;45:91-99.
19. Turner JH, Claringbold PG, Berger JD, et al. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: An experimental model in the rat. Nucl Med Commun 1992;13:321-329.
20. Mill WB. Radiation therapy in multiple myeloma. Radiology 1975;115:175-178.
21. Bosch A, Frias Z. Radiotherapy in the treatment of multiple myeloma. Int J Radiat Oncol Biol Phys 1988;15:1363-1369.
22. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.
23. Brenner W, Kampen WU, Kampen AM, Henze E. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 2001;42:230-236. (Pubitemid 32150513)
24. Franzius C, Schuck A, Bielack SS. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:1953-1954. (Pubitemid 34273292)
25. Dispenzieri A, Wiseman GA, Lacy MQ, et al. A phase I study of 153Sm-EDTMP with fixed high dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005;19:118-125.
26. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
27. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
28. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2526.
29. Giralt S, Bensinger W, Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 2003;102:2684-2691.
30. Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 2007;13:543-549.
31. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90-95.
32. Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27:1653-1659.
33. Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: Biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm 2002;17:151-163.
34. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control 2002;9:106-113.
35. Gertz MA, Lacy MQ, Inwards DJ, et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000;26:45-50. (Pubitemid 30456108)